Dupixent 300 MG/2 ML pen 2ML
Ended Awarded
- Contract number
- SPE2DB26FVGYP
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $38,505
Award facts
- Contract value 100% obligated
- $38,504.51 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at approximately $38.5K to AmerisourceBergen Drug Corp for the supply of Dupixent (dupilumab) 300 mg/2 mL pen auto-injectors. The award, issued on November 12, 2025, with completion expected by November 13, 2025, represents a firm fixed-price delivery order with no set-aside designation, indicating competitive award. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform fulfillment from its corporate office location. This delivery order falls under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99M prime vendor agreement running through December 2026 that enables comprehensive pharmaceutical support across military healthcare systems worldwide.
As a critical vendor for federal medical procurement, AmerisourceBergen Drug Corp supplies pharmaceuticals and medical products to support Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. Dupixent is a specialty biologic medication used to treat conditions such as atopic dermatitis, asthma, and chronic rhinosinusitis, reflecting DLA's ongoing procurement of specialized therapeutics for military personnel and beneficiaries. The firm fixed-price structure and expedited completion timeline indicate this delivery represents an urgent replenishment order within the broader pharmaceutical prime vendor framework that DLA utilizes to maintain consistent medical supply chains across the military healthcare enterprise.
Quick answers
Who was awarded contract SPE2DB26FVGYP?
SPE2DB26FVGYP was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on November 12, 2025.
How much is contract SPE2DB26FVGYP worth?
The government has obligated $38,505 on SPE2DB26FVGYP.
Is contract SPE2DB26FVGYP an order under another contract?
Yes. SPE2DB26FVGYP is a delivery order under SPE2DB25D3017, an indefinite delivery contract.
Was contract SPE2DB26FVGYP competed?
The extent of competition for SPE2DB26FVGYP was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award